Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis, a Pre-Revenue China Biopharma, Files for Hong Kong IPO

publication date: May 9, 2018

Ascletis Pharma of Hangzhou has the honor of being the first pre-revenue China biopharma to file for a Hong Kong IPO. Previously, a company had to show two years of profitability before the exchange would consider a filing. Ascletis is close to completing regulatory review of a two-drug combo that treats hepatitis C with a 99% success rate. It plans to offer the regimen in China at a discount to Gilead Sciences' Harvoni and Solvaldi, which have changed the treatment paradigm for hepatitis C in western countries. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.